Despite pervasive AI marketing at JPM—on billboards, in presentations, and even on Uber apps—the industry has yet to see a fully AI-designed drug reach approval. This gap highlights a technology hype cycle where branding and perceived necessity are currently outpacing proven, real-world outcomes in drug discovery.

The long-term strategy for AI in drug discovery is a two-step process. First, create an AI platform to design effective drugs. Second, after a dozen or so AI-designed drugs succeed, use that data to convince regulators to trust AI predictions, potentially allowing future drugs to skip steps like animal testing and accelerate trials.

The lengthy timelines of drug development create a significant perception lag for AI's impact. Molly Gibson clarifies that molecules currently in clinical trials were designed years ago using nascent AI models. The true capabilities of today's more advanced AI platforms won't be evident in approved drugs for several more years.

While AI excels at screening vast compound libraries for potential drug candidates, it cannot overcome the ultimate bottleneck: the messy, complex, and poorly documented reality of human biology. The need for physical clinical trials remains the fundamental constraint on medical progress.

The Cleveland Clinic's sepsis model reduced mortality by 41% despite not being perfect. This case study demonstrates that AI's true utility is in achieving substantial, incremental gains over existing systems, rather than the hyped-up promise of flawless, silver-bullet solutions.

The path to curing diseases with AI is less about a model discovering a magic pill and more about the industrial and economic effects. For example, a founder getting rich from an AI image generator can then fund advanced screening technology, which reduces cancer rates through earlier detection.

As AI achieves impressive milestones, like assisting in creating a cancer vaccine, the public conversation immediately discounts the achievement. The goalposts shift from "AI helped solve a problem" to demanding a fully autonomous, one-shot solution. This pattern of escalating expectations obscures the real, incremental progress being made.

AI models will produce a few stunning, one-off results in fields like materials science. These isolated successes will trigger an overstated hype cycle proclaiming 'science is solved,' masking the longer, more understated trend of AI's true, profound, and incremental impact on scientific discovery.

Despite the buzz, a clinical development expert cautions that AI's impact in drug development is limited. The primary bottleneck isn't the algorithms but the lack of sufficient, high-quality human biological data that can be translated into reliable predictions, as animal models often fail to provide it.